SMMT Q1 2022 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$250,000+30.2% YoY

Gross Profit

$250,000100.0% margin

Operating Income

-$22M-8863.2% margin

Net Income

-$21M-8558.8% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

-0.4%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$116M

Total Liabilities

$52M

Stockholders' Equity

$64M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$250,000	$192,000	+30.2%
Gross Profit	$250,000	$192,000	+30.2%
Operating Income	-$22M	-$17M	-30.9%
Net Income	-$21M	-$17M	-22.4%

Revenue Segments

License and Service

$250,000100%

Geographic Segments

Latin America

$250,000100%